Risks

Negative interest coverage and a current ratio near 1.1 leave AYTU more exposed than larger healthcare peers if refinancing costs rise or working capital tightens.

A 158-day DSO and 129-day inventory build imply slower cash realization than leaner peers, increasing liquidity pressure and limiting flexibility for growth investment.

A 59-day cash conversion cycle is materially longer than asset-light pharma distributors and diagnostics peers, so modest demand softness can translate into outsized cash strain.

Net debt remains manageable, but AYTU’s leverage is less forgiving than better-capitalized peers, making earnings volatility more consequential for covenant and funding access.

Opportunities

AYTU’s low net debt-to-EBITDA provides more balance-sheet room than highly levered small-cap healthcare peers, supporting resilience if operating conditions improve.

A quick ratio near 1.0 compares favorably with weaker-liquidity peers, giving AYTU a narrower but usable buffer to absorb near-term working-capital swings.

If receivables and inventory normalize, AYTU can convert working capital faster than peers with structurally heavier cash needs, improving reinvestment capacity.

In a fragmented small-cap healthcare market, even modest margin stabilization can have a larger relative impact on AYTU than on larger peers with steadier earnings bases.

Overall Score

AYTU’s forward positioning is constrained by weak interest coverage and slow working-capital conversion, while low net leverage and near-adequate liquidity provide some peer-relative resilience.